Profile data is unavailable for this security.
About the company
Travere Therapeutics, Inc. is a biopharmaceutical company. The Company is focused on identifying, developing, and delivering life-changing therapies to people living with rare kidney and metabolic diseases. Its product, FILSPARI (sparsentan), is indicated to reduce proteinuria in adults with primary IgAN at risk of rapid disease progression. Sparsentan is also in late-stage development for focal segmental glomerulosclerosis (FSGS). The Company’s Pegtibatinase is a novel investigational human enzyme replacement candidate being evaluated for the treatment of classical homocystinuria (HCU), which is a rare metabolic disorder. Its commercial products, Thiola and Thiola EC are for the treatment of cystinuria, a rare genetic cystine transport disorder that causes high cystine levels in the urine and the formation of recurring kidney stones. It is also engaged in the identification of potential small molecule therapeutics for Alagille syndrome (ALGS).
- Revenue in USD (TTM)155.72m
- Net income in USD-415.73m
- Incorporated2008
- Employees380.00
- LocationTravere Therapeutics Inc3611 Valley Centre Dr, Suite 300SAN DIEGO 92130United StatesUSA
- Phone+1 (760) 260-8600
- Fax+1 (302) 645-1280
- Websitehttps://travere.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Y-mAbs Therapeutics Inc | 84.50m | -21.67m | 522.64m | 100.00 | -- | 5.27 | -- | 6.19 | -0.496 | -0.496 | 1.93 | 2.26 | 0.6481 | 1.31 | 4.30 | 844,990.00 | -16.62 | -44.23 | -19.95 | -50.45 | 86.53 | -- | -25.64 | -181.13 | 5.67 | -- | 0.00 | -- | 29.96 | -- | 77.58 | -- | -- | -- |
| Northwest Biotherapeutics Inc | 1.34m | -72.21m | 523.10m | 25.00 | -- | -- | -- | 391.54 | -0.0629 | -0.0629 | 0.0012 | -0.0447 | 0.0435 | -- | -- | 53,440.00 | -228.72 | -381.58 | -- | -- | -- | -- | -5,258.91 | -6,479.25 | -- | -10.49 | -- | -- | 14.80 | 36.21 | 38.71 | -- | 77.88 | -- |
| Celcuity Inc | 0.00 | -73.45m | 527.57m | 55.00 | -- | 3.46 | -- | -- | -2.79 | -2.79 | 0.00 | 4.35 | 0.00 | -- | -- | 0.00 | -41.61 | -37.32 | -44.44 | -39.16 | -- | -- | -- | -- | -- | -- | 0.2193 | -- | -- | -- | -57.99 | -- | -31.12 | -- |
| Terns Pharmaceuticals Inc | 0.00 | -91.06m | 530.35m | 66.00 | -- | 2.24 | -- | -- | -1.26 | -1.26 | 0.00 | 3.66 | 0.00 | -- | -- | 0.00 | -33.23 | -41.34 | -34.55 | -45.70 | -- | -- | -- | -31,010.30 | -- | -- | 0.00 | -- | -- | -- | -49.49 | -- | -26.60 | -- |
| Entrada Therapeutics Inc | 162.87m | 23.49m | 532.72m | 160.00 | 25.16 | 1.97 | 19.89 | 3.27 | 0.6273 | 0.6273 | 4.79 | 8.02 | 0.3302 | -- | 3.89 | 1,024,359.00 | 4.76 | -- | 7.06 | -- | -- | -- | 14.42 | -- | -- | -- | 0.00 | -- | -- | -- | 92.93 | -- | -- | -- |
| Corbus Pharmaceuticals Holdings Inc | 0.00 | -33.76m | 535.40m | 19.00 | -- | 5.43 | -- | -- | -6.97 | -6.97 | 0.00 | 9.23 | 0.00 | -- | -- | 0.00 | -38.06 | -86.84 | -49.24 | -130.46 | -- | -- | -- | -769.76 | -- | -15.43 | 0.1179 | -- | -- | -- | -5.33 | -- | -- | -- |
| Heron Therapeutics Inc | 132.10m | -80.95m | 542.35m | 126.00 | -- | -- | -- | 4.11 | -0.6156 | -0.6156 | 0.9316 | -0.2245 | 0.6021 | 1.20 | 2.26 | 1,048,405.00 | -36.90 | -53.55 | -56.71 | -71.24 | 57.08 | 52.52 | -61.28 | -170.12 | 1.90 | -- | 1.29 | -- | 17.99 | 10.40 | 39.26 | -- | -29.97 | -- |
| Travere Therapeutics Inc | 155.72m | -415.73m | 545.85m | 380.00 | -- | 7.37 | -- | 3.51 | -5.32 | -2.00 | 2.04 | 0.9732 | 0.2116 | 1.57 | 7.04 | 409,800.00 | -56.49 | -36.95 | -71.19 | -44.77 | 94.34 | 95.92 | -266.96 | -165.79 | 2.75 | -- | 0.836 | -- | 32.69 | -2.43 | -13.54 | -- | 16.49 | -- |
| Third Harmonic Bio Inc | 0.00 | -29.60m | 545.86m | 31.00 | -- | 2.04 | -- | -- | -0.7475 | -0.7475 | 0.00 | 6.55 | 0.00 | -- | -- | 0.00 | -10.53 | -- | -10.70 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | 12.32 | -- | -- | -- |
| Neurogene Inc | 0.00 | -39.03m | 552.83m | 91.00 | -- | 3.21 | -- | -- | -4.58 | -4.58 | 0.00 | 13.28 | 0.00 | -- | -- | 0.00 | -26.57 | -32.70 | -28.41 | -34.73 | -- | -- | -- | -- | -- | -- | 0.0006 | -- | -- | -- | 36.90 | -- | 45.63 | -- |
| Mind Medicine (MindMed) Inc | 0.00 | -125.32m | 556.29m | 57.00 | -- | 2.81 | -- | -- | -2.94 | -2.94 | 0.00 | 2.76 | 0.00 | -- | -- | 0.00 | -58.14 | -- | -73.35 | -- | -- | -- | -- | -- | -- | -- | 0.0675 | -- | -- | -- | -68.55 | -- | -- | -- |
| PepGen Inc | 0.00 | -80.33m | 559.20m | 64.00 | -- | 3.12 | -- | -- | -3.25 | -3.25 | 0.00 | 5.53 | 0.00 | -- | -- | 0.00 | -39.37 | -- | -42.42 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -13.78 | -- | -- | -- |
| Savara Inc | 0.00 | -64.49m | 563.81m | 37.00 | -- | 4.63 | -- | -- | -0.3848 | -0.3848 | 0.00 | 0.8819 | 0.00 | -- | -- | 0.00 | -44.84 | -36.86 | -47.26 | -39.54 | -- | -- | -- | -102,587.50 | -- | -- | 0.1782 | -- | -- | -- | -43.38 | -- | 15.91 | -- |
| Esperion Therapeutics Inc | 229.74m | -86.51m | 566.49m | 240.00 | -- | -- | -- | 2.47 | -1.00 | -1.00 | 1.76 | -1.57 | 0.7353 | 0.7415 | 5.05 | 957,250.00 | -27.69 | -69.45 | -47.42 | -101.81 | 81.85 | -- | -37.65 | -147.44 | 1.78 | -0.6581 | -- | -- | 54.14 | -- | 10.45 | -- | -- | -- |
| Lexeo Therapeutics Inc | 0.00 | -69.42m | 572.59m | 58.00 | -- | 3.13 | -- | -- | -2.71 | -2.71 | 0.00 | 5.56 | 0.00 | -- | -- | 0.00 | -47.71 | -- | -54.30 | -- | -- | -- | -- | -- | -- | -- | 0.0091 | -- | -100.00 | -- | -12.01 | -- | -- | -- |
Data as of May 30 2024. Currency figures normalised to Travere Therapeutics Inc's reporting currency: US Dollar USD
67.14%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| Armistice Capital LLCas of 31 Mar 2024 | 7.50m | 9.85% |
| Deep Track Capital LPas of 31 Mar 2024 | 7.37m | 9.68% |
| SSgA Funds Management, Inc.as of 31 Mar 2024 | 6.61m | 8.68% |
| BlackRock Fund Advisorsas of 31 Mar 2024 | 6.10m | 8.01% |
| The Vanguard Group, Inc.as of 31 Mar 2024 | 6.07m | 7.97% |
| Macquarie Investment Management Business Trustas of 31 Mar 2024 | 4.61m | 6.06% |
| Rock Springs Capital Management LPas of 25 Apr 2024 | 4.41m | 5.80% |
| Morgan Stanley & Co. LLCas of 31 Mar 2024 | 3.34m | 4.39% |
| Renaissance Technologies LLCas of 31 Mar 2024 | 2.86m | 3.76% |
| Pictet Asset Management SAas of 31 Mar 2024 | 2.24m | 2.94% |
More ▼
Data from 31 Mar 2024 - 31 Mar 2024Source: FactSet Research Systems Inc.
